Free Research Report Download:
The Cancer Market Outlook To 2014
Free Pharmaceutical Market Research Reports
Biotechnology
Corporate & Fiscal
Drug Delivery
Health Products
Hospital Markets
Indication Areas
Medical Devices
Prescription Medicines
R&D
Custom Research
Pharmaceutical Events & Conferences
Contact
Terms & Conditions
Privacy
Home >
The Pharmaceutical Market: Denmark
Management Report
Published: January 2010
Pages: 58
Tables: For full details, please email keithw@cmsinfo.com
From: GBP 595.00 Buy Now!
Research from: Espicom
Sector: Prescription Medicines
Espicom’s in-depth pharmaceutical market reports are ideal for executives wanting to understand the key drivers in pharmaceutical markets and have access to a wealth of statistical data. Each report opens with an outlook section that provides analysis of the market, 5-year market forecasts, national data projections, market outlook and key developments such as regulation, pricing/reimbursement, intellectual property, health facilities and government policy. The report also provides extensive background information, population trends, health status, health expenditure, organisation & administration, hospital services, medical personnel, healthcare development, market access information, trade data for raw materials and finished products and essential industry contacts. Included with the report are 3 free quarterly updated outlook reports, enabling you to keep up to date with market developments for a year.
Denmark has a stable political system and a stable economy. However, it was hit hard by the global economic downturn, with GDP contracting by 5.1% in 2009, according to figures from the Economist Intelligence Unit. GDP growth is projected to rise gradually to 0.5% in 2010 and 2.0% by 2015. Meanwhile, healthcare expenditure has continued its steady growth in the past few years, increasing by 7.1% to reach DKK118.3 billion (US$21.7 billion) in 2007, with private expenditure accounting for around 16% of the total.
Although companies are free to set their own prices, products will only be reimbursed at the level of the lowest generic drug in each class unless it can be shown that there is a distinct therapeutic benefit. This has proved to be an effective way to drive pharmaceutical prices down.
Over 17,000 people are employed in the Danish pharmaceutical industry, including people employed in the production of raw materials, production of pharmaceuticals and wholesales. There is strong domestic production although many producers focus on Denmark’s export market, therefore many pharmaceutical imports are in retail-ready packages.
Due to the presence of Novo Nordisk, Denmark is a major global supplier of insulin in retail form. This has resulted in a long-standing balance of trade surplus, which was in excess of US$4.7 billion in 2008. Between 2004 and 2008, imports increased by a CAGR of 11.9% to US$3.2 billion, while exports increased by a CAGR of 10.5% to US$7.9 billion.
Leo Pharma announced its acquisition of Australian dermatology specialist Peplin for US$287.5 million in September 2009. In the same month, the company announced it is to reacquire the licensing rights to its psoriasis portfolio, currently held by Warner Chilcott.
Lundbeck announced around 200 job cuts in Denmark in September 2009, in an effort to reduce costs. Other cost-saving measures that the company is implementing are insourcing and changing the travel behaviour of employees.
Highly detailed report content
MARKET OUTLOOK
Key national data projections
Pharmaceutical Market Analysis
Current market size
Market structure
Unique 5-year market projections
Imports
Domestic manufacturing
Exports
Research & development
Pharmaceutical regulatory analysis
Including regulation, pricing & reimbursement and intellectual property
Pharmaceutical distribution
Healthcare analysis
Including demographics, healthcare system, health expenditure, healthcare infrastructure and personnel HEALTHCARE DATA
A comprehensive tabula review of the market, including economic indicators, demographics, health expenditure, hospital and primary care data, and healthcare personnel.
Although companies are free to set their own prices, products will only be reimbursed at the level of the lowest generic drug in each class unless it can be shown that there is a distinct therapeutic benefit. This has proved to be an effective way to drive pharmaceutical prices down.
Over 17,000 people are employed in the Danish pharmaceutical industry, including people employed in the production of raw materials, production of pharmaceuticals and wholesales. There is strong domestic production although many producers focus on Denmark’s export market, therefore many pharmaceutical imports are in retail-ready packages.
Due to the presence of Novo Nordisk, Denmark is a major global supplier of insulin in retail form. This has resulted in a long-standing balance of trade surplus, which was in excess of US$4.7 billion in 2008. Between 2004 and 2008, imports increased by a CAGR of 11.9% to US$3.2 billion, while exports increased by a CAGR of 10.5% to US$7.9 billion.
Leo Pharma announced its acquisition of Australian dermatology specialist Peplin for US$287.5 million in September 2009. In the same month, the company announced it is to reacquire the licensing rights to its psoriasis portfolio, currently held by Warner Chilcott.
Lundbeck announced around 200 job cuts in Denmark in September 2009, in an effort to reduce costs. Other cost-saving measures that the company is implementing are insourcing and changing the travel behaviour of employees.
Highly detailed report content
MARKET OUTLOOK
Key national data projections
Pharmaceutical Market Analysis
Current market size
Market structure
Unique 5-year market projections
Imports
Domestic manufacturing
Exports
Research & development
Pharmaceutical regulatory analysis
Including regulation, pricing & reimbursement and intellectual property
Pharmaceutical distribution
Healthcare analysis
Including demographics, healthcare system, health expenditure, healthcare infrastructure and personnel HEALTHCARE DATA
A comprehensive tabula review of the market, including economic indicators, demographics, health expenditure, hospital and primary care data, and healthcare personnel.